Over 70 years of non-small cell lung cancer drug pemetrexed single first-line treatment of clinical observation.docVIP

Over 70 years of non-small cell lung cancer drug pemetrexed single first-line treatment of clinical observation.doc

  1. 1、本文档共10页,可阅读全部内容。
  2. 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  5. 5、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  6. 6、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  7. 7、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  8. 8、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
Over 70 years of non-small cell lung cancer drug pemetrexed single first-line treatment of clinical observation

 PAGE \* MERGEFORMAT 10 Over 70 years of non-small cell lung cancer drug pemetrexed single first-line treatment of clinical observation [Keywords:] pemetrexed, non-small cell lung cancer, efficacy, median survival Non-small cell lung cancer (NSCLC) accounts for about 80% Feiai, mostly through the occult, the time of diagnosis about 2 / 3 of patients lose the opportunity to surgery, chemotherapy treatment for the main one (1), with the Feiai new and effective drug development the progress of applications, and comprehensive treatment, the treatment improved the survival time is extended (2). to platinum-based combination chemotherapy is the standard first-line treatment of advanced NSCLC treatment. However, for elderly patients, especially older than 70-year-old patients, their functional status and organ function reserve tend to be relatively low, in the course of treatment will cause the platinum chemotherapy-related side effects increased. Therefore, the American Society of Clinical Oncology recommendations for elderly patients with advanced NSCLC patients with high efficiency and low toxicity can be a single agent chemotherapy. Pemetrexed is a multi-target anti-folate drugs, can inhibit folate-dependent enzymes play a Duozhong anti-tumor effect, with high efficiency and low toxicity characteristics (3). For this reason, in recent years, we have some 70 patients with advanced NSCLC over the age of using single-agent pemetrexed first-line treatment, and its efficacy and related factors were observed to provide the basis for clinical treatment. 1 Materials and Methods 1.1 General Information Choose from March 2006 to May 2007 in our hospital patients, were confirmed by pathology or cytology of b ~ NSCLC patients, no major organ dysfunction, blood, liver and kidney function and heart, Coagulation function was normal, with measurable or evaluable tumor lesions, to follow-up. A total of 33 patients were included, 21 males and 12 females, aged 70.1

文档评论(0)

hhuiws1482 + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

版权声明书
用户编号:5024214302000003

1亿VIP精品文档

相关文档